Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

4 treatments under study, led by Dexmedetomidine

Research Leaders

5 sponsors active, led by University of Roma La Sapienza

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 4 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

3Total
Phase 2 (1)
Phase 4 (2)

Trial Status

Completed4

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 4 completed trials

Clinical Trials (4)

Showing 4 of 4 trials
NCT03723538CompletedPrimary

Dexmedetomidine Use for Sedation in Patients Submitted to Tracheal Surgery

NCT01507363Phase 4Completed

Analgesic Effect of Gabapentin in Total Knee Arthroplasty (TKA)

NCT00393003Phase 4CompletedPrimary

Target-controlled Infusion of Propofol and Remifentanil for Postoperative Sedation Guided by the Bispectral Index

NCT00125398Phase 2CompletedPrimary

GPI 15715 For Sedation in the Intensive Care Unit (ICU) Setting

Showing all 4 trials

Research Network

Common Treatments

  • Dexmedetomidine1
  • Aquavan Fospropofol Disodium Gpi 157151
  • Gabapentin1
  • Closedloop Anesthesia System1

Active Sponsors

  • University of Roma La Sapienza1
  • Hvidovre University Hospital1
  • Eisai Inc.1
  • Hopital Foch1
  • Lundbeck Foundation1

Top Investigators

Related Conditions

  • Intubation1
  • Respiration Artificial1
  • Postoperative Pain1

Activity Timeline